Does Rallies show 13F holders for EVO?

Yes. Rallies tracks hedge fund and 13F ownership data for EVO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is EVO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for EVO. It does not provide personalized investment advice.

EVO (Evotec SE American Depositary Shares) Stock Analysis - Hedge Fund Holdings

Evotec SE American Depositary Shares (EVO) is a publicly traded Healthcare sector company. As of May 21, 2026, EVO trades at $2.89 with a market cap of $973.22M and a P/E ratio of 0.00. EVO moved +2.70% today. Year to date, EVO is -10.97%; over the trailing twelve months it is -30.22%. Its 52-week range spans $2.31 to $5.64. Analyst consensus is buy with an average price target of $5.50. Rallies surfaces EVO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns EVO stock?

Hedge funds tracked by Rallies that own EVO include Citadel Advisors. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Evotec SE American Depositary Shares.

EVO Key Metrics

Key financial metrics for EVO
Metric	Value
Price	$2.89
Market Cap	$973.22M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.07%
52-Week High	$5.64
52-Week Low	$2.31
Volume	789
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Top Hedge Funds Holding EVO

Citadel Advisors holds 27.46K shares of EVO, changed +139.95% as of Sep 30, 2024.

Latest EVO News

Evotec Places €116.1M Convertible Bonds Due 2033 at 2.625% Interest — May 12, 2026
Evotec Secures Gates Grants to Finance $9.9M TB Pipeline Expansion — Apr 30, 2026
Evotec Names 20-Year Life Sciences Executive Dr. Ingrid Müller as COO to Lead Horizon Initiative — Apr 15, 2026
Evotec Cuts 800 Jobs, Sees 1.1% Revenue Drop and €75M Cost Savings Plan — Apr 8, 2026
Evotec Subsidiary Secures up to $10 Million BARDA Award for Ebola Antibody Manufacturing — Mar 23, 2026

Recent EVO Insider Trades

Abood Thomas J. bought 120.26K (~$300.66K) on Apr 16, 2018.
Yeros John Peter bought 50.00K (~$150.00K) on Apr 16, 2018.
BANK OF AMERICA CORP /DE/ bought 100 (~$1.28K) on Oct 18, 2011.

EVO Analyst Consensus

3 analysts cover EVO: 0 strong buy, 2 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.50.

Common questions about EVO

Who owns EVO stock?: Hedge funds tracked by Rallies that own EVO include Citadel Advisors. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Evotec SE American Depositary Shares.
Does Rallies show 13F holders for EVO?: Yes. Rallies tracks hedge fund and 13F ownership data for EVO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is EVO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for EVO. It does not provide personalized investment advice.